ETTX · Entasis Therapeutics Holdings Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $37.10M | $41.02M | $40.17M | $25.75M |
| SG&A | $15.21M | $13.21M | $13.77M | $5.60M |
| Total Operating Expenses | $52.32M | $54.23M | $53.94M | $31.34M |
| D&A | $104.0K | $141.0K | $142.0K | $164.0K |
| Operating Income | ($52.32M) | ($54.23M) | ($46.94M) | ($31.34M) |
| Interest Expense | - | - | - | - |
| Income Tax | - | $0 | $677.0K | $472.0K |
| Net Income | ($47.14M) | ($50.50M) | ($43.85M) | ($29.92M) |
| EPS - Basic | ($2.10) | - | - | - |
| EPS - Diluted | ($2.10) | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Cash & Equivalents | $32.31M | $53.25M | $16.03M | $49.36M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $1.18M | $660.0K | $1.30M | $1.37M |
| Current Assets | $39.81M | $60.13M | $49.01M | $88.79M |
| Total Assets | $40.92M | $61.56M | $51.03M | $89.27M |
| Current Liabilities | $9.71M | $8.56M | $7.56M | $6.22M |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $9.71M | $9.27M | $8.88M | $6.39M |
| Stockholders' Equity | $31.21M | $52.29M | $42.16M | ($26.34M) |
| Retained Earnings | ($231.60M) | ($184.46M) | ($133.96M) | ($90.11M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Operating Cash Flow | ($42.97M) | ($45.43M) | ($44.74M) | ($27.16M) |
| Investing Cash Flow | ($70.0K) | $24.98M | $11.36M | ($286.0K) |
| Financing Cash Flow | $22.10M | $57.66M | $57.0K | $56.29M |
| CapEx | $70.0K | $18.0K | $105.0K | $286.0K |
| Free Cash Flow | ($43.04M) | ($45.44M) | ($44.85M) | ($27.45M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 0.91 | 0.90 | 1.02 | 0.92 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -115.2% | -82.0% | -85.9% | -33.5% |
| Return on equity | -151.0% | -96.6% | -104.0% | 113.6% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 4.10 | 7.02 | 6.49 | 14.28 |
| Quick ratio | 4.10 | 7.02 | 6.49 | 14.28 |
| Cash ratio | 3.33 | 6.22 | 2.12 | 7.94 |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | - | - | - |
| Equity multiplier | 1.31 | 1.18 | 1.21 | -3.39 |
| Liabilities / Assets | 0.24 | 0.15 | 0.17 | 0.07 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | 3.5% | -15.5% | -49.7% | - |
| Net income growth (YoY) | 6.6% | -15.2% | -46.5% | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | 5.3% | -1.3% | -63.4% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -40.3% | 24.0% | - | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Entasis Therapeutics Holdings Inc. against the 5 most active filers in the same SIC group.